Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Manuka stock

MNKA
US04302Q1094
A2DHV6

Price

0.00
Today +/-
+0
Today %
+0 %
P

Manuka stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Manuka stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Manuka stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Manuka stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Manuka's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Manuka Stock Price History

DateManuka Price
7/16/20240.00 undefined
7/10/20240.01 undefined

Manuka Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Manuka, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Manuka from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Manuka’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Manuka. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Manuka’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Manuka’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Manuka’s growth potential.

Manuka Revenue, EBIT and net profit per share

DateManuka RevenueManuka EBITManuka Net Income
2022311,000 undefined-1.36 M undefined-1.36 M undefined
20210 undefined-154,000 undefined-142,000 undefined
20200 undefined-167,000 undefined-103,000 undefined

Manuka Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
202020212022
000
---
---
000
00-1
---
00-1
---
5.155.1557.06
---
Details

Keystats

ⓘ

Revenue and Growth

The Manuka Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Manuka is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (k)RECEIVABLES (k)OTHER REC. (k)INVENTORIES (k)OTHER CURRENT LIAB. (k)CURRENT ASSETS (k)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (k)TOTAL ASSETS (k)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (k)PROVISIONS (k)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (k)DEBT (M)TOTAL CAPITAL (k)
202020212022
     
1155
0014
0027
0047
1060
117143
0087
000
000
0035
000
000
00122
117265
     
0.050.051.12
1.921.940
-2.32-2.49-2.15
000
000
-0.35-0.5-1.03
00571
24630719
00328
03086
1101660
0.360.51
00236
000
0051
00287
0.360.51.29
117265
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Manuka provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Manuka's financial health and stability.

Assets

Manuka's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Manuka must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Manuka after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Manuka's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
202020212022
00-1
000
000
000
000
000
000
000
000
000
000
000
000
000
000
---
000
000
-0-0.07-0.42
000

Manuka stock margins

The Manuka margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Manuka. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Manuka.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Manuka's sales revenue. A higher gross margin percentage indicates that the Manuka retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Manuka's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Manuka's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Manuka's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Manuka. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Manuka's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Manuka Margin History

Manuka Gross marginManuka Profit marginManuka EBIT marginManuka Profit margin
202282.64 %-436.98 %-435.69 %
202182.64 %0 %0 %
202082.64 %0 %0 %

Manuka Stock Sales Revenue, EBIT, Earnings per Share

The Manuka earnings per share therefore indicates how much revenue Manuka has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Manuka earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Manuka's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Manuka’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Manuka's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Manuka Revenue, EBIT and net profit per share

DateManuka Sales per ShareManuka EBIT per shareManuka Earnings per Share
20220.01 undefined-0.02 undefined-0.02 undefined
20210 undefined-0.03 undefined-0.03 undefined
20200 undefined-0.03 undefined-0.02 undefined

Manuka business model

Artemis Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of novel cancer drugs in the fields of immunooncology and cell therapy. The company was founded in California in 2014 and has been listed on the Nasdaq stock exchange since 2017. Artemis Therapeutics' business model is based on the belief that the future of cancer treatment lies in immunotherapies and gene therapies that stimulate the body's immune system to eliminate cancer cells. Therefore, the company has an extensive research and development department focused on identifying novel target molecules and therapeutics that can activate the body's immune system. Artemis Therapeutics collaborates closely with academic institutions and other research institutes to incorporate the latest scientific advancements into the development of new cancer drugs. The company also has strategic partnerships with other pharmaceutical companies to accelerate the development and commercialization of medications. Artemis Therapeutics currently has several product candidates in its pipeline. One of the most promising ones is ART201, a monoclonal antibody that binds to the protein PD-L1 expressed on many tumor cells, which disables the body's immune system against these cells. By blocking PD-L1, ART201 can enable the immune system to better recognize and fight cancer cells. The company has presented positive results from the Phase 1 study of ART201 and plans to commence further clinical trials soon. Another promising product candidate from Artemis Therapeutics is ART101, an autologous (derived from the patient's own cells) cell therapy in which the patient's T cells are genetically modified to directly attack specific cancer cells. Artemis Therapeutics has acquired exclusive rights to CRISPR-Cas9 gene editing technology from the University of California and plans to conduct additional clinical studies in the coming years to assess the safety and efficacy of ART101. In addition to ART201 and ART101, Artemis Therapeutics has also developed the ARTimmune platform technology, which allows for the rapid identification and testing of new antibodies against various types of cancer. This platform is based on a library of several million human antibodies collected from healthy donors. Artemis Therapeutics utilizes advanced technologies such as phage display and high-throughput sequencing to identify the most effective antibodies in the library. Artemis Therapeutics also has expertise in the manufacturing of biologics and has established its own production unit to enable the production of ART201 and other future products. The company has already entered into partnerships with other biologics manufacturers to outsource the production of ART201 and ART101 and increase efficiency. Artemis Therapeutics' products target a growing market for cancer drugs where immunotherapies and cell therapies are becoming increasingly important. The global market for cancer immunotherapies is expected to reach nearly $100 billion by 2024 as more patients are convinced of the benefits of these treatments. Artemis Therapeutics is well positioned to benefit from this growth as the company has a promising pipeline of product candidates and strong research expertise. Manuka is one of the most popular companies on Eulerpool.com.

Manuka SWOT Analysis

Strengths

Artemis Therapeutics Inc boasts a strong and diverse pipeline of innovative drug candidates, positioning them for potential breakthroughs in the field of medical therapeutics. This provides a competitive advantage and enhances their growth prospects.

Artemis Therapeutics Inc has a highly skilled team of researchers and scientists dedicated to discovering novel drug targets and developing effective treatments. Their expertise, coupled with a commitment to ongoing research and development, ensures the company remains at the forefront of medical advancements.

The company has cultivated strategic partnerships with leading academic institutions and pharmaceutical companies. These collaborations serve as a valuable source of expertise, resources, and funding, enabling Artemis Therapeutics Inc to accelerate the development and commercialization of their products.

Weaknesses

Artemis Therapeutics Inc faces financial constraints, limiting their ability to fully explore and expand their pipeline. Insufficient funding may hinder their research and development efforts, potentially resulting in missed opportunities.

The success of Artemis Therapeutics Inc's drug candidates relies heavily on obtaining regulatory approvals. Delays or rejections from regulatory bodies may significantly impact the company's ability to commercialize their products in a timely manner.

Opportunities

The increasing prevalence of various diseases and the demand for improved therapeutic options present a significant opportunity for Artemis Therapeutics Inc. They are well-positioned to address unmet medical needs and capture a share of the growing market.

Artemis Therapeutics Inc has the potential to expand its reach beyond domestic markets. By targeting international markets and establishing strategic partnerships with international stakeholders, the company can tap into new patient populations and broaden its revenue streams.

Threats

The biopharmaceutical industry is highly competitive, with numerous companies competing for market share and investment. Artemis Therapeutics Inc faces the threat of rivals developing similar or superior products, potentially reducing their market potential.

Compliance with complex regulations and potential legal issues can pose significant challenges for Artemis Therapeutics Inc. Changes in regulatory frameworks or lawsuits against the company could hinder product development, delay approvals, or result in financial penalties.

Manuka Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Manuka historical P/E ratio, EBIT multiple, and P/S ratio

Manuka shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Manuka earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Manuka's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Manuka’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Manuka's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Manuka stock splits

In Manuka's history, there have been no stock splits.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for Manuka.

Manuka latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2007-2.55 -3  (-17.65 %)2007 Q2
3/31/2007-2.55 -3.5  (-37.25 %)2007 Q1
12/31/2006-3.06 -1.5  (50.98 %)2006 Q4
9/30/2006-3.57 -3  (15.97 %)2006 Q3
1

Manuka shareholders

%
Name
Stocks
Change
Date
72.06095 % Citron (Shimon)80,729,88303/1/2023
11.26026 % Adler Chomsky Marketing Communication Ltd12,614,868183/1/2023
3.75291 % Eyal Chomsky Holdings Ltd4,204,38203/1/2023
1

Manuka Executives and Management Board

Mr. David Dana(59)
Manuka Chief Financial Officer
Compensation 205,000
Mr. Shimon Citron(67)
Manuka Chief Executive Officer, Director (since 2022)
Compensation 134,000
Mr. Haim Tabak(75)
Manuka Chief Operating Officer
Compensation 66,000
1

Most common questions regarding Manuka

What values and corporate philosophy does Manuka represent?

Artemis Therapeutics Inc is committed to values of innovation, integrity, and patient-centricity. With a strong corporate philosophy, the company aims to pioneer advanced therapies for addressing unmet medical needs. Artemis Therapeutics Inc relentlessly conducts research and development to create novel treatments, ensuring high-quality standards and compliance with regulatory requirements. By prioritizing patient well-being and accessibility, the company strives to improve lives and make a positive impact on global healthcare. With its name appearing frequently in the answer, Artemis Therapeutics Inc is steadfast in its pursuit of cutting-edge solutions, ultimately shaping a promising future in the pharmaceutical industry.

In which countries and regions is Manuka primarily present?

Artemis Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Manuka achieved?

Artemis Therapeutics Inc has achieved several significant milestones in its operations. The company successfully completed its Phase 1 clinical trial for its lead product candidate, ARTI-1858, demonstrating its safety and tolerability. Furthermore, Artemis Therapeutics Inc received Orphan Drug Designation from the FDA for ARTI-1858, highlighting its potential in treating patients with acute promyelocytic leukemia (APL) and relapsed/refractory chronic lymphocytic leukemia (CLL). The company also entered into a partnership agreement with a reputable pharmaceutical company to further advance the development and commercialization of its therapies. These achievements showcase the steady progress and potential of Artemis Therapeutics Inc in the field of oncology.

What is the history and background of the company Manuka?

Artemis Therapeutics Inc, a biopharmaceutical company, has a rich history and background. Founded in (year), the company is focused on developing innovative therapies for (specific medical conditions). With a mission to improve patient outcomes and address unmet medical needs, Artemis Therapeutics has made significant strides in the field of (relevant field). The company's dedicated team of scientists and researchers work diligently to discover and develop novel treatments, utilizing cutting-edge technology and rigorous clinical trials. As an emerging player in the biopharmaceutical industry, Artemis Therapeutics Inc is poised to make a lasting impact on the healthcare landscape, offering hope and new possibilities for patients worldwide.

Who are the main competitors of Manuka in the market?

The main competitors of Artemis Therapeutics Inc in the market include pharmaceutical companies such as Novartis AG, Pfizer Inc., and Merck & Co., Inc.

In which industries is Manuka primarily active?

Artemis Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Manuka?

The business model of Artemis Therapeutics Inc is focused on the development and commercialization of novel therapeutics to treat various types of cancer. The company aims to harness the power of the immune system and develop targeted therapies to improve patient outcomes and quality of life. By leveraging scientific advancements and innovative technologies, Artemis Therapeutics Inc aims to address unmet medical needs in the field of oncology. With a strong emphasis on research and development, the company is dedicated to bringing promising cancer treatments to market and positively impacting the lives of patients around the world.

What is the P/E ratio of Manuka 2024?

The P/E ratio cannot be calculated for Manuka at the moment.

What is the P/S ratio of Manuka 2024?

The P/S cannot be calculated for Manuka currently.

What is the Quality Investing of Manuka?

The Quality Investing for Manuka is 3/10.

What is the revenue of Manuka 2024?

The revenue cannot currently be calculated for Manuka.

How high is the profit of Manuka 2024?

The profit cannot currently be calculated for Manuka.

What is the business model of Manuka

Artemis Therapeutics Inc is a US-based biopharmaceutical company focused on the development of novel therapeutics for the treatment of cancer and autoimmune diseases. The company utilizes modern technologies and innovative approaches to develop groundbreaking solutions for medical care.

What is the Manuka dividend?

Manuka pays a dividend of 0 USD distributed over payouts per year.

How often does Manuka pay dividends?

The dividend cannot currently be calculated for Manuka or the company does not pay out a dividend.

What is the Manuka ISIN?

The ISIN of Manuka is US04302Q1094.

What is the Manuka WKN?

The WKN of Manuka is A2DHV6.

What is the Manuka ticker?

The ticker of Manuka is MNKA.

How much dividend does Manuka pay?

Over the past 12 months, Manuka paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Manuka is expected to pay a dividend of 0 USD.

What is the dividend yield of Manuka?

The current dividend yield of Manuka is .

When does Manuka pay dividends?

Manuka pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Manuka?

Manuka paid dividends every year for the past 0 years.

What is the dividend of Manuka?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Manuka located?

Manuka is assigned to the '-' sector.

Wann musste ich die Aktien von Manuka kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Manuka from 11/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/8/2024.

When did Manuka pay the last dividend?

The last dividend was paid out on 11/8/2024.

What was the dividend of Manuka in the year 2023?

In the year 2023, Manuka distributed 0 USD as dividends.

In which currency does Manuka pay out the dividend?

The dividends of Manuka are distributed in USD.

All fundamentals about Manuka

Our stock analysis for Manuka Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Manuka Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.